Morrow A L, Creese I
Mol Pharmacol. 1986 Apr;29(4):321-30.
[3H]Prazosin and [3H]WB4101 [2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4 benzodioxane] have both been proposed to label alpha 1-adrenergic receptors in the rat central nervous system. As many discrepancies between the binding of these two ligands have arisen, we conducted these studies in order to reevaluate their binding characteristics and resolve the similarities and differences in the pharmacological characteristics of their respective binding sites. [3H]Prazosin binding is characterized by a monophasic saturation isotherm. Prazosin, indoramine, and dihydroergocryptine competitions with [3H]prazosin are steep and monophasic, and model best to a single binding site. In contrast, phentolamine and WB4101 competition curves are shallow in rat cortex, exhibiting Hill coefficients significantly less than 1.0, and model to two binding sites of approximately equal proportions. The higher and lower affinity components are defined as alpha 1A and alpha 1B, respectively. [3H]WB4101 also labels two binding sites in rat cortex and hippocampus with picomolar and nanomolar affinity, respectively. However, the nanomolar binding site is serotonergic and not adrenergic. The picomolar site (KD = 150 pm) has characteristics of an alpha 1-receptor binding site: prazosin, WB4101, and phentolamine affinities for this [3H]WB4101 binding site correlate with their affinities for the highest affinity component (alpha 1A) of [3H]prazosin binding. In addition, the Bmax of this [3H] WB4101-labeled site is equal to one-half of the total [3H]prazosin Bmax. Agonist competitions with [3H]prazosin binding are multiphasic with pseudo-Hill slopes less than 1.0 and with a rank order of affinity of epinephrine greater than norepinephrine greater than phenylephrine. When binding to the alpha 1A component is blocked by a 30 nM phentolamine mask, the same rank order of agonist affinities is preserved. Although the affinities of epinephrine and norepinephrine at the two subtypes are identical, phenylephrine is weaker at the alpha 1B site. The ratio of the potency of phentolamine versus prazosin is about 4 at the alpha 1A component but about 80 at the alpha 1B binding site. We discuss these data in relation to the reported potencies of these antagonists in blocking alpha 1-receptor-mediated responses which may correlate with our designation of alpha 1A or alpha 1B binding sites.
[3H]哌唑嗪和[3H]WB4101[2-(2,6-二甲氧基苯氧基乙基)氨基甲基-1,4-苯并二恶烷]均被提议用于标记大鼠中枢神经系统中的α1-肾上腺素能受体。由于这两种配体的结合之间出现了许多差异,我们进行了这些研究,以重新评估它们的结合特性,并解析它们各自结合位点在药理学特性上的异同。[3H]哌唑嗪结合的特征是单相饱和等温线。哌唑嗪、吲哚胺和双氢麦角隐亭与[3H]哌唑嗪的竞争是陡峭且单相的,并且最适合单一结合位点模型。相比之下,酚妥拉明和WB4101在大鼠皮层中的竞争曲线较平缓,希尔系数显著小于1.0,适合两个比例大致相等的结合位点模型。较高亲和力和较低亲和力成分分别定义为α1A和α1B。[3H]WB4101在大鼠皮层和海马体中也标记了两个结合位点,亲和力分别为皮摩尔和纳摩尔。然而,纳摩尔结合位点是5-羟色胺能的而非肾上腺素能的。皮摩尔位点(KD = 150皮摩尔)具有α1-受体结合位点的特征:哌唑嗪、WB4101和酚妥拉明对这个[3H]WB4101结合位点的亲和力与它们对[3H]哌唑嗪结合的最高亲和力成分(α1A)的亲和力相关。此外,这个[3H]WB4101标记位点的Bmax等于总[3H]哌唑嗪Bmax的一半。与[3H]哌唑嗪结合的激动剂竞争是多相的,伪希尔斜率小于1.0,激动剂亲和力的顺序为肾上腺素大于去甲肾上腺素大于苯肾上腺素。当与α1A成分的结合被30 nM酚妥拉明掩盖时,激动剂亲和力的相同顺序得以保留。尽管肾上腺素和去甲肾上腺素在两种亚型上的亲和力相同,但苯肾上腺素在α1B位点较弱。酚妥拉明与哌唑嗪的效价比在α1A成分处约为4,但在α1B结合位点约为80。我们结合这些拮抗剂在阻断α1-受体介导反应中的报道效价来讨论这些数据,这些效价可能与我们对α1A或α1B结合位点的指定相关。